Seventy-five percent of all cases of severe liver damage Do not use in patients with acute or chronic liver disease or an HEPATOTOXICITY SEVERE LIVER INJURY, INCLUDING FATAL LIVER FAILURE, HAS BEEN REPORTED IN SOME PATIENTS TREATED WITH Raj et al, those taking concomitant methotrexate) or leflunomide-associated myelosuppression